TREM2 expression in the brain and biological fluids in prion diseases by Diaz‑Lucena, Daniela et al.
Vol.:(0123456789) 
Acta Neuropathologica (2021) 141:841–859 
https://doi.org/10.1007/s00401-021-02296-1
ORIGINAL PAPER
TREM2 expression in the brain and biological fluids in prion diseases
Daniela Diaz‑Lucena1,2 · Niels Kruse3 · Katrin Thüne4 · Matthias Schmitz4,5 · Anna Villar‑Piqué1,2 · 
Jose Eriton Gomes da Cunha6 · Peter Hermann4 · Óscar López‑Pérez1,2 · Pol Andrés‑Benito1,2 · Anna Ladogana7 · 
Miguel Calero8,9 · Enric Vidal10 · Joachim Riggert11 · Hailey Pineau12 · Valerie Sim12 · Henrik Zetterberg13,14,15,16 · 
Kaj Blennow13,14 · Jose Antonio del Río17,18,19,20 · Alba Marín‑Moreno21 · Juan Carlos Espinosa21 · 
Juan María Torres21 · Raquel Sánchez‑Valle22 · Brit Mollenhauer23,24 · Isidre Ferrer1,2,25  · Inga Zerr4,5 · 
Franc Llorens1,2,4
Received: 23 February 2021 / Revised: 15 March 2021 / Accepted: 15 March 2021 / Published online: 21 April 2021 
© The Author(s) 2021
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface receptor that regulates microglial 
function and is involved in the pathophysiology of several neurodegenerative diseases. Its soluble form (sTREM2) results 
from shedding of the TREM2 ectodomain. The role of TREM2 in prion diseases, a group of rapidly progressive dementias 
remains to be elucidated. In the present study, we analysed the expression of TREM2 and its main sheddase ADAM10 in the 
brain of sporadic Creutzfeldt-Jakob disease (sCJD) patients and evaluated the role of CSF and plasma sTREM2 as a poten-
tial diagnostic marker of prion disease. Our data indicate that, compared to controls, TREM2 is increased in sCJD patient 
brains at the mRNA and protein levels in a regional and subtype dependent fashion, and expressed in a subpopulation of 
microglia. In contrast, ADAM10 is increased at the protein, but not the mRNA level, with a restricted neuronal expression. 
Elevated CSF sTREM2 is found in sCJD, genetic CJD with mutations E200K and V210I in the prion protein gene (PRNP), 
and iatrogenic CJD, as compared to healthy controls (HC) (AUC = 0.78–0.90) and neurological controls (AUC = 0.73–0.85), 
while CSF sTREM2 is unchanged in fatal familial insomnia. sTREM2 in the CSF of cases with Alzheimer’s disease, and 
multiple sclerosis was not significantly altered in our series. CSF sTREM2 concentrations in sCJD are PRNP codon 129 
and subtype-related, correlate with CSF 14-3-3 positivity, total-tau and YKL-40, and increase with disease progression. 
In plasma, sTREM2 is increased in sCJD compared with HC (AUC = 0.80), displaying positive correlations with plasma 
total-tau, neurofilament light, and YKL-40. We conclude that comparative study of TREM2 in brain and biological fluids 
of prion diseases reveals TREM2 to be altered in human prion diseases with a potential value in target engagement, patient 
stratification, and disease monitoring.
Keywords TREM2 · Prion diseases · Creutzfeldt-Jakob disease · Microglia · Cerebrospinal fluid · Plasma
Introduction
Prion diseases (or transmissible spongiform encephalopa-
thies) are a rare group of invariably fatal neurodegenerative 
dementias characterized by a rapid progression affecting 
humans and animals. The causative agent of prion dis-
eases is the pathological form of the cellular prion protein 
 (PrPc),  PrPSc, which nucleates and self-propagates in the 
central nervous system (CNS) [3]. However, the mecha-
nisms by which  PrPSc causes neurodegeneration are not 
well-understood.
Human prion diseases can be classified according to their 
aetiology as sporadic Creutzfeldt-Jakob disease (sCJD); 
genetic Creutzfeldt-Jakob disease (gCJD), Gerstmann-Sträu-
ssler-Scheinker syndrome (GSS), and fatal familial insomnia 
(FFI); and as iatrogenic Creutzfeldt-Jakob disease (iCJD), 
variant Creutzfeldt-Jakob disease (vCJD), and Kuru. sCJD 
is the most prevalent human prion disease and its typical 
clinical phenotype includes rapidly progressive dementia, 
behavioural abnormalities, ataxia, extrapyramidal features, 
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and myoclonus. Eventually, sCJD patients fall into a state of 
akinetic mutism before death [18, 54]. Neuropathologically, 
sCJD is characterized by neuronal loss, spongiform change, 
reactive astrocytosis, and microgliosis. These changes are 
accompanied by the accumulation of a protease-resistant 
form of host-derived prion protein  (PrPres) [17].
A clinical diagnosis of probable sCJD is achieved by the 
combination of clinical symptoms and signs, neuroimaging, 
and cerebrospinal fluid tests (CSF) [23, 26]. The most rel-
evant CSF biomarkers are surrogate neuronal damage mark-
ers 14-3-3, total-tau (t-tau), and α-synuclein (a-syn), while 
the real-time quaking induced conversion (RT-QuIC) assay 
is a prion-specific assay allowing identification of the patho-
logical prion protein in the CSF [70]. Recently, some blood 
biomarkers have been shown to be suitable in discriminating 
sCJD cases but their accuracy in the differential diagnosis of 
sCJD has not been determined [30, 66, 72]. Therefore, they 
are not yet included in clinical practice. Importantly, the use 
of surrogate CSF biomarkers is not limited to diagnostic pur-
poses; rather, a potential use as prognostic, predictive, moni-
toring, and response biomarkers has been proposed [35, 46, 
65, 71]. Therefore, the characterization of the best putative 
application for each biomarker as well as the identification 
of biomarkers targeting the complete pathological signatures 
of prion disease will greatly enhance the rational develop-
ment and interpretation of future therapeutic interventions. 
In this regard, the observation that exacerbated inflamma-
tory profiles is an early pathogenic event in prion diseases 
[2, 34] has led to the search for surrogate biomarkers of 
neuroinflammation for early diagnosis. In this context, glial-
specific proteins such as the S100 calcium-binding protein 
B (S100B), chitinase-3-like protein 1 (CHI3L1/YKL-40), 
chitotriosidase 1 (CHIT1), and the glial fibrillary acidic pro-
tein (GFAP) have been reported to be increased in the CSF 
of sCJD [2, 25, 37, 58].
In recent years, strong evidence of a link between TREM2 
function in the innate immune system and the pathogen-
esis of neurodegenerative diseases has been documented. 
Although rare in the population, certain TREM2 variants 
are associated with increased risk of developing neurode-
generative diseases such as Alzheimer’s disease (AD) [21, 
26], frontotemporal dementia [20, 56], Parkinson’s disease 
[56], and amyotrophic lateral sclerosis [7], presumably as 
a consequence of TREM2 loss of function [12]. In this 
regard, TREM2 mutations led to reduced phagocytic func-
tion [64], while injection of sTREM2 in an AD mouse model 
enhanced microglial proliferation, migration, clustering in 
the vicinity of amyloid plaques, and the uptake and degrada-
tion of β-amyloid [79]. In AD patients, increased TREM2 
levels have been reported in the CSF [22, 24, 41, 42, 55], 
together with positive immunoreactivity in the microglia 
associated with β-amyloid plaques and in neuritic pathology-
enriched areas [41]. It is currently accepted that TREM2 is 
expressed predominantly in cells of myeloid lineage, in line 
with its role in brain innate immune function [15, 28, 61]. 
No effect of genetic variation in TREM2 in the risk of CJD 
has been identified [63]. Yet pioneering studies have shown 
increased microglial TREM2 mRNA expression in scrapie-
infected mice and prion-inoculated TREM2 knockout mice, 
with attenuated microglia response compared to controls 
but no alterations in prion pathogenesis in terms of disease 
onset, disease duration, and presence of pathological PrP 
[80]. TREM2 expression in brain and biological fluids of 
human prion diseases and its potential role as a candidate 
biomarker of prion pathogenesis have not been explored.
Material and methods
Antibodies and reagents
Human TREM2 goat polyclonal antibody (RD Systems, 
AF1828) was used diluted 1:20 for immunohistochemistry 
and at a dilution of 1:200 for western blotting. The anti-
body anti-TREM2 Abcam [EPR20243] ab209814 diluted 
1:100 was used for immunohistochemistry for comparative 
purposes. Human ADAM10 antibody (Abcam, ab1997) was 
used at a dilution of 1:75 for immunohistochemistry and 
1:500 for western blotting. Monoclonal anti-β-actin antibody 
(Sigma-Aldrich, A5316) was used at 1:30,000 as a protein-
loading control in western blotting. For double-labelling 
immunofluorescence and confocal microscopy visualization, 
TREM2 was combined with the microglial marker IBA1 
diluted 1:1000 (Wako, 019-19,741).
Brain samples
Brain tissue was obtained from the Institute of Neuropa-
thology HUB-ICO-IDIBELL Biobank and the Hospital 
Clinic de Barcelona-IDIBAPS Neurological Tissue Bank 
following the Spanish legislation guidelines on this mat-
ter (Real Decreto de Biobancos 1716/2011) and approval 
of the local ethics committees. Processing of brain tissue 
has been detailed elsewhere [16]. The post-mortem interval 
between death and tissue processing was between 1 h 30 min 
and 24 h. One hemisphere was immediately cut in coronal 
sections, 1-cm thick, and selected areas of the encephalon 
were rapidly dissected, frozen on metal plates over dry ice, 
placed in individual air-tight plastic bags, numbered with 
water-resistant ink, and stored at − 80 °C until use for bio-
chemical studies. The other hemisphere was fixed by immer-
sion in 4% buffered formalin for 3 weeks for morphologic 
study. Neuropathological examination was performed in 
every case on formalin-fixed, paraffin-embedded samples. 
De-waxed paraffin Sects. 4 microns thick were stained with 
haematoxylin and eosin, periodic acid Schiff, Congo red, 
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and Klüver-Barrera, or processed for immunohistochemis-
try using anti-β-amyloid, p-tau (clone AT8), α-synuclein, 
αB-crystallin, TDP-43, P-TDP-43, ubiquitin, p62, glial 
fibrillary acidic protein, CD68, and IBA1, as previously 
reported [16]. Neuropathological diagnosis of Alzheimer’s 
disease (AD) was categorized following Braak stages of neu-
rofibrillary tangle pathology adapted to paraffin sections [5, 
6]. Cases with Frontotemporal lobar degeneration with TDP-
43 pathology (FTLD-TDP) were diagnosed following estab-
lished neuropathological criteria [43]. Post-mortem neuro-
pathological examination confirmed the diagnosis of sCJD 
cases according to established criteria [49, 50]. The analysis 
of the codon129 genotype of PrP gene (PRNP) (methionine 
or valine) was performed after isolation of genomic DNA 
from blood samples according to standard methods. sCJD 
type 1 or type 2 classification was performed with western 
blotting. Cases with associated pathologies such as vascu-
lar diseases, infections of the nervous system, neoplastic 
diseases affecting the nervous system, systemic and central 
immune diseases, metabolic syndrome, hypoxia, and pro-
longed axonal states such as those occurring in intensive 
care units were excluded from the present study.
Since a percentage of CJD cases have concomitant NFT 
pathology at stages 0-III of Braak, with occasional amy-
loid plaques (stage A of Braak), control cases in the present 
series are not controls without NFT pathology but rather 
age-matched controls with NFT pathology at stages 0-III 
without neurological symptoms. Mild small blood vessel 
disease and occasional status cribosus occurred in the ‘con-
trol’ and ‘pathological’ groups.
Molecular studies were carried out in frontal cortex 
area 8 (FC) and the cerebellum (CB). The CJD group was 
composed of controls (n = 15 FC, n = 12 CB), sCJD (n = 11 
FC, n = 12 CB), and sCJD VV2 (n = 11 FC, n = 10 CB). The 
sFTLD group consisted of samples from the FC of con-
trols (n = 17) and sFTLD-TDP (n = 16). Details of the brain 
samples used for q-PCR are summarized in Supplementary 
Table 1. Samples for western blotting were obtained from 10 
controls, 8 sCJD MM1, and 8 sCJD VV2 cases.
Triggering receptor expressed on myeloid cells 2 immu-
nohistochemistry was performed on de-waxed paraffin 
sections of controls (n = 10; 7 M, 3 F; mean age ± SD: 
57.9 ± 12.5), CJD MM1 (n = 7; 6 M, 1 not available; mean 
age ± SD: 63.8 ± 13.9), AD V-VI (n = 3; 3 F; mean age ± SD: 
77.3 ± 4.1), sFTLD-TDP (n = 3; 3  M; mean age ± SD: 
72 ± 7.1), DLB (n = 3; 2F,1 M; mean age ± SD: 78.3 ± 4.9), 
ALS (n = 4; 3 F, 1 M; mean age ± SD: 62 ± 12.5), white 
matter with plaques of relapsing remitting cases of multiple 
sclerosis (MS, n = 1 M, 52 years), and vascular dementia 
with subacute areas of infarction (DM, n = 3 M; 72) (see 
Supplementary table 3).
Cerebrospinal fluid and plasma samples
Cerebrospinal fluid (CSF) samples (Table 1) from healthy 
control individuals (HC, n = 48), patients with non-primarily 
neurodegenerative neurological diseases (ND, n = 64), AD 
(n = 35), and sCJD (n = 139) were collected at the Clinical 
Dementia Centre and the National Reference Centre for CJD 
Surveillance at the University Medical Centre of Göttingen 
(Germany) and at the Alzheimer’s Disease and Other Cogni-
tive Disorders Unit, Hospital Clínic de Barcelona, Barcelona 
(Spain). Patients with sCJD, classified as probable (n = 47) 
or definite (n = 92) cases according to diagnostic consensus 
Table 1  Biomarker characteristics of the cases used in the CSF cohort of study. Diagnostic groups included controls (HC, ND), prion diseases 
(sCJD, gCJD-E200K, gCJD-V210I, FFI and iCJD), and AD cases
Number of cases (n), age [mean value ± standard deviation (SD)], sex distribution (f female, m male), CSF sTREM2 [mean value ± SD, and 95% 
confidence interval (95% CI)] and t-tau (mean value ± SD) concentrations as well as 14-3-3 positivity (pos/positive, neg/negative) are indicated. 
Inconclusive 14-3-3 tests were considered as negative. Significant associations (p value) between sTREM2 with sex and age for each diagnostic 
group are reported. *For 13 cases, t-tau data were not available. (NA not available)
n Sex (f/m) Age sTREM2 (pg/
mL)
95% CI tau (pg/mL) 14-3-3 p value
Mean + SD Mean + SD Mean + SD Pos/neg sTREM2 vs. 
sex
sTREM2 vs. age
HC 48 26/22 64 ± 15 1898 ± 842 1653–2143 246 ± 132 0/48 0.26 0.20
ND 64 39/25 66 ± 9 2321 ± 1125 2040–2602 441 ± 410 13/49 0.87 0.61
sCJD 139 73/66 66 ± 11 6975 ± 8523 5544–8403 7337 ± 7658* 118/21 0.83 0.26
gCJD—E200K 57 35/22 60 ± 10 6341 ± 8128 4184–8498 6548 ± 5688 49/8 0.13 0.91
gCJD—V210I 34 18/16 66 ± 10 8231 ± 10,257 4652–11,810 10,548 ± 9985 27/7 0.18 0.63
FFI—D178N-
M
26 9/17 50 ± 12 2871 ± 2704 1779–3963 993 ± 1715 4/22 0.22 0.19
iCJD 10 5/5 50 ± 11 4709 ± 2712 3025–6036 12,171 ± 10,053 8/2 0.42 0.44
AD 35 22/13 67 ± 10 2896 ± 1603 2345–3447 633 ± 401 NA 0.41 0.25
844 Acta Neuropathologica (2021) 141:841–859
1 3
criteria [76], genetic CJD (n = 91), iatrogenic CJD (n = 10), 
and fatal familial insomnia (FFI, n = 26) were collected in 
the following CJD reference centres: (1) Clinical Dementia 
Centre and the National Reference Centre for CJD Surveil-
lance at the University Medical Centre, Göttingen, Germany, 
(2) Alzheimer’s Disease and Other Cognitive Disorders 
Unit, Hospital Clínic, Barcelona, Spain, (3) National Cen-
tre of Microbiology-Carlos III Institute of Health, Madrid, 
Spain, and (4) Istituto Superiore di Sanità, Rome, Italy. The 
diagnosis of genetic prion diseases was carried out accord-
ing to surveillance criteria after prion protein gene (PRNP) 
analysis [31] and following World Health Organization 
(WHO) criteria [73]. Iatrogenic CJD was diagnosed accord-
ing to established WHO criteria [73]. Nine iatrogenic cases 
were associated with dura mater grafts and one with corneal 
transplantation. AD cases were diagnosed according to the 
National Institute on Aging—Alzheimer’s Association work-
groups (NIA-AA) criteria [45].
In addition, CSF was obtained from patients with relaps-
ing/remitting multiple sclerosis [69] at the Multiple Sclero-
sis Unit, Service of Neurology, Bellvitge University Hospital 
(n = 16), and the Clinical Dementia Centre and the National 
Reference Centre for CJD Surveillance at the University 
Medical Centre of Göttingen (Germany) (n = 13 (Supple-
mentary table 4).
Cerebrospinal fluid tests in healthy controls (HC) was 
obtained from patients for knee surgical procedures under 
spinal anaesthesia.
The ND group was composed of cases diagnosed with 
neurological diseases not associated with neurodegenera-
tive pathology and included the following diagnostic groups: 
psychosis, paranoid psychosis, bipolar disorder, schizophre-
nia, ischemic stroke, multiple infarct, epilepsy, meningitis, 
alcohol abuse, vertigo, acute or chronic headache, pain syn-
dromes, acute hypoxia, polyneuropathy, cerebral lymphoma, 
astrocytoma, and paraneoplasic syndromes. ND cases were 
diagnosed according to acknowledged standard neurologic 
clinical and para-clinical findings based on the International 
Classification of Diseases 10th Revision definitions.
Blood was collected in Plasma-EDTA tubes at the 
Department of Transfusion Medicine (healthy controls, HC; 
n = 97 cases) and at the Department of Neurology (sCJD 
cases, n = 86 cases) of the University Medical Centre Göt-
tingen (Germany) under standardized pre-analytical con-
ditions. The healthy control (HC) group was composed of 
healthy blood donors without any relevant clinical findings 
(Table 2).
For the analysis of CSF sTREM2 concentrations at differ-
ent disease stages in sCJD, we divided the time from lum-
bar puncture (LP) or blood uptake to disease onset in each 
patient by the total duration of the disease. Then, samples 
were grouped into three categories according to whether 
they underwent LP/blood uptake in the first (time of LP to 
disease onset/total duration of the disease < 0.33), second 
(0.33–0.66), or third (> 0.66) stage of the disease, as previ-
ously reported [59].
CSF and plasma tests
Soluble TREM2 (sTREM2) concentrations in the CSF and 
plasma were quantified with a previously described immu-
noassay [29] using the electrochemiluminescence-based 
MesoScale Discovery platform. Inter- and intra-assay 
coefficients of variation in our study were below 12% and 
10%, respectively. CSF from MS cases was assessed in two 
series. In the first, the method was the previously described 
immunoassay [29], while for the second series (Bellvitge) 
assessment was made using the Human TREM2 ELISA Kit 
(Abcam, ab224881). CSF total-tau (t-tau) was quantified 
using a commercially available colorimetric enzyme-linked 
immunosorbent assay (INNOTEST hTAU-Ag from Fujire-
bio). CSF was analysed for the presence of 14 to 3-3 protein 
using western blotting [75]. CSF and plasma YKL-40 were 
quantified using the MicroVue YKL-40 ELISA kit from 
Quidel. Plasma neurofilament light (NfL) and t-tau concen-
trations were measured using commercially available assays 
on the Single molecule array (SIMOA) HD-1 instrument 
(Quanterix). The analysts were masked to clinical data.
Animal experimentation
We conducted animal experiments in accordance with the 
Code for Methods and Welfare Considerations in Behav-
ioural Research with Animals (Directive 2010/63/EU) 
Table 2  Demographic and 
biomarker characteristics of the 
cases used in the plasma cohort 
study
Diagnostic groups included HC and sCJD. Number of cases (n), age: mean value ± standard deviation 
(SD), sex distribution (f female, m male), and plasma sTREM2 concentrations: mean value ± SD and 95% 
confidence interval (95% CI) are indicated. Significant associations (p value) between sTREM2 with sex 
and age for each diagnostic group are indicated
n Sex (f/m) Age sTREM2 pg/mL) 95% CI p values
Mean + SD Mean + SD sTrem2 vs. Sex sTrem2 vs. age
HC 97 23/74 64 ± 5 4409 ± 3961 3611–5208 0.58 0.12
sCJD 86 52/34 65 ± 8 8981 ± 8932 7066–10,896 0.94 0.11
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and made every effort to minimize suffering. Experiments 
developed in the Centro de Investigación en Sanidad Ani-
mal–Instituto Nacional de Investigación y Tecnología 
Agraria y Alimentaria (Madrid, Spain) were evaluated by 
the Committee on the Ethics of Animal Experiments of the 
Instituto Nacional de Investigación y Tecnología Agraria 
y Alimentaria and approved by the General Directorate of 
the Madrid Community Government (permit no. PROEX 
094/18). The tg340 and tg361 mouse lines expressing about 
four-fold level of human PrPM129 and PrPV129 on a mouse 
PrP null background were used as mouse models of sCJD 
MM1 and sCJD VV2 subtypes. Individually identified 6-to-
10-week-old mice were anaesthetized and inoculated with 
2 mg of a 10% (w/v) brain homogenate of sCJD MM1 (in 
the tg340 mouse line) and sCJD VV2 (in the tg361) in the 
right parietal lobe using a 25-gauge disposable hypodermic 
needle. Control animals for each genotype were inoculated 
with control brain homogenates. Mice were observed daily 
and their neurological status was assessed weekly. At 80, 
120, or 180 days post-inoculation (dpi) animals were eutha-
nized, necropsy was performed, and the brain was removed. 
Four to eight animals per time point and condition were used 
for RT-qPCR assays.
Western blotting
Human tissues were lysed in RIPA lysis buffer RIPA (NaCl 
1 M, Nonidet P-40 1%, sodium deoxycholate 0.5%,SDS 
0.1%, Tris 50 mM, pH 7.4) supplemented with protease, and 
phosphatase inhibitors (Roche, GE). After centrifugation at 
14,000g for 20 min at 4 °C, supernatants were quantified 
for protein concentration (BCA, Pierce), mixed with SDS-
PAGE sample buffer, boiled, and subjected to 4–12% BisTris 
Gels  (NuPAGE™ 4 to 12%, Bis–Tris, 1.5 mm, Mini Protein 
Gel, 15-well, ThermoFisher NP0336BOX). Gels were trans-
ferred onto PVDF membranes and processed for specific 
immunodetection. Membranes were incubated overnight at 
4 °C with primary antibodies and with appropriate horserad-
ish peroxidase-conjugated secondary antibody (anti-mouse/
anti-rabbit HRP-IgG) diluted at 1:2000 (Dako) for 1 h at 
room temperature. Chemiluminescence immunodetection 
was performed using the ECL-Amersham (GE Healthcare) 
kit. Densitometry was carried out with the ImageJ software 
and values were normalized using β-actin levels.
Real‑time polymerase chain reaction (qPCR)
RNA from different human and mouse brain regions was 
purified using RNeasy Plus Mini Kit (Qiagen, 74,136), 
which eliminates genomic DNA contamination. RNA integ-
rity was assessed with the RNA Integrity Number (RIN 
value) determined with the Agilent 2100 Bioanalyzer (Agi-
lent) (RIN values between 4 and 9.2). Reverse transcription 
of the RNA samples was carried out using the High-Capac-
ity cDNA Reverse Transcription kit (Applied Biosystems) 
following the supplier’s instructions. Quantitative RT-PCR 
assays were performed in duplicate on cDNA samples in 
384-well optical plates with ABI Prism 7900 Sequence 
Detection System (Applied Biosystems, Life Technologies). 
The reactions were carried out using 20xTaqMan Gene 
Expression Assays and 2xTaqMan Universal PCR Mas-
ter Mix (Applied Biosystems) with the following probes: 
CD68 Hs00154355_m1, TREM2 human Hs00219132_m1, 
TREM2 mouse Mm04209424_g1, and ADAM10 human 
Hs00153853_m1. The reactions were conducted using the 
following parameters: 50 °C for 2 min, 95 °C for 10 min, 
and 40 cycles with 95 °C for 15 s and 60 °C for 1 min. The 
fold change was determined by the ΔΔCt method, in which 
each target gene is normalized to its endogenous control 
to obtain the ΔCt. Afterwards, each ΔΔCt is determined 
by subtracting the mean-ΔCt of the control group samples 
to the ΔCt of each sample. Finally, these ΔΔCt values are 
used as the negative exponent with base 2 to obtain the fold 
change per sample. Mean fold change values were analysed 
with appropriate statistical test indicated in each figure 
using GraphPad Prism 6.01. Gene expression levels were 
normalized to the housekeeping genes Glucuronidase beta 
(GUSB) Hs00939627_m1 NM_000181.3 or glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) Hs03929097_g1 
NM_001289745.1 for human and, GAPDH Mm99999915_
g1 NM_001289726.1 for mouse (Applied Biosystems).
Immunohistochemistry
De-waxed sections, 4 microns thick, were processed for 
immunohistochemistry. The sections were boiled in citrate 
buffer to retrieve antigenicity, followed by endogenous per-
oxidase blockage (Dako Real peroxidase blocking solution 
S2023). All sections were incubated overnight at 4 °C with 
primary antibodies diluted in Dako Real Antibody Diluent 
(Dako S2022).
Primary antibody anti-human TREM2 (RD Systems 
AF1828) diluted 1:20, anti-human TREM2 (Abcam, 
ab209814) diluted 1:100, and anti-human ADAM10 
(Abcam, 1997) diluted 1:150 were used. Detection was 
achieved by incubation with R.T.U. Biotinylated Universal 
Antibody (Abcam ab64257) for 10 min at room temperature, 
followed by R.T.U. HRP-Streptavidin (Abcam ab64269). 
The peroxidase reaction was visualized with diaminoben-
zidine and  H2O2. Control of the immunostaining included 
omission of the primary antibody.
Immunofluorescence
De-waxed sections, 4 microns thick, were boiled in citrate 
buffer to enhance antigenicity, and afterwards were stained 
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with a saturated solution of Sudan black B (Merck, DE) 
to block auto-fluorescence of lipofuscin granules present 
in cell bodies. Then they were rinsed in 70% ethanol and 
washed in distilled water. All sections were blocked at 
room temperature with 10% foetal bovine serum diluted 
in PBS, and incubated at 4ºC overnight with combina-
tions of primary antibodies. After washing, the sections 
were incubated with Alexa-488 and Alexa-555 (Molecu-
lar Probes, Eugene, Oregon, USA) fluorescence secondary 
antibodies. Nuclei were stained with  DRAQ5™ (dilution 
1:2,000, BioStatus, Loughborough, UK). After washing, 
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the sections were mounted in Immuno-Fluore mounting 
medium (ICN Biomedicals, Irvine, CA, USA), sealed, 
and dried overnight. Sections were examined with a Leica 
TCS-SL confocal microscopy.
Statistical analysis
For brain tissue data, in two group comparisons, non-para-
metric Mann–Whitney-U tests were used. For comparisons 
between multiple groups, Kruskal–Wallis tests followed by 
Dunn’s post-hoc test or one-way ANOVA followed by Tukey 
post-hoc test were applied after testing for normality. Bio-
marker data were log-transformed, and linear models were 
built controlling for the effect of age and sex. To assess the 
diagnostic accuracy of sTREM2, receiver operating char-
acteristic (ROC) curve analyses were carried out and areas 
under the curve (AUC) with confidence intervals (95% CI) 
were calculated. Spearman rank correlation coefficients were 
used to assess associations between continuous biomarker 
levels. Statistical comparison between ROC curves was 
made with the pROC R package [57]. Longitudinal analysis 
of sTREM2 along disease stages was conducted with nlme 
R package [53] using a multilevel linear model that assumed 
a fixed slope for disease stage.
Results
TREM2 and ADAM10 expression in the brain of sCJD 
patients
Expression of TREM2 was analysed in the frontal cortex 
(FC) and cerebellum (CB) of sCJD MM1 and VV2 cases. 
With RT-qPCR analysis, TREM2 mRNA was significantly 
increased in the FC of sCJD MM1 (n = 14, p < 0.001, fold 
change 6.1) and VV2 (n = 14, p < 0.001, fold change 3.5) 
cases compared to controls (n = 15). TREM2 mRNA expres-
sion was higher in sCJD cases possessing the PRNP gene 
codon 129 MM1 as compared to VV2 genotype (p < 0.05) 
(Fig.  1a). In the CB, TREM2 mRNA was significantly 
increased in sCJD VV2 (n = 10, p < 0.001) and MM1 (n = 12, 
p < 0.05) compared to controls (n = 12) (Fig. 1b). TREM2 
levels were normalized to GAPDH, and similar results 
were obtained for GUSB normalization (data not shown). 
Increased TREM2 mRNA expression in the FC in sCJD was 
significant (n = 28, p < 0.001) when compared with FTLD-
TDP (n = 16) (Fig. 1c).
Western blot analysis revealed significantly increased pro-
tein levels of mature and total TREM2 (mature plus imma-
ture forms) in the FC of sCJD cases compared to controls 
(p < 0.001, control vs. sCJD MM1 and p < 0.01, control vs. 
sCJD VV2 for total TREM2) (Fig. 1d). The expression of 
mature and total TREM2 was significantly higher in sCJD 
MM1 cases compared to sCJD VV2 (p < 0.05). In the CB, 
mature and total TREM2 was significantly higher in sCJD 
cases compared to controls (p < 0.05 in all comparisons) 
(Fig. 1d). In both brain regions, 10 controls, 8 sCJD MM1, 
and 8 sCJD VV2 cases were used.
In immunohistochemistry study of control brains using 
the TREM2 polyclonal RD Systems, AF1828H antibody dis-
closed immunostaining in the blood vessel walls, with no 
immunostaining of neurons or glial cells (data not shown). 
Using the same antibody, TREM2 immunoreactivity in 
sCJD MM1 brains was observed in the blood vessel walls 
and in microglia; neurons were not immunostained with 
this antibody (Fig. 1e). De-waxed paraffin sections of AD, 
DLB, MS, sALS, and VD cases showed TREM2 immuno-
reactivity in the blood vessels and microglia surrounding 
β-amyloid plaques in AD, lipid-laden macrophages in suba-
cute MS plaques, macrophages and a few mononuclear cells 
in subacute infarcts, and a few microglia in the spinal cord 
in sALS. Neurons were not stained with this antibody (data 
not shown). To validate immunohistochemical data, double-
labelling immunofluorescence against TREM2 and Iba-1 in 
the FC of sCJD MM1 cases disclosed TREM2 localization 
in a subpopulation of microglial cells as revealed with the 
IBA1 antibody (Fig. 1f). Additionally, TREM2 mRNA in 
Fig. 1  TREM2 expression in sCJD brain tissue. RT-qPCR analysis of 
TREM2 in: a the frontal cortex (FC) and b cerebellum (CB) of con-
trol, sCJD MM1, and sCJD VV2 cases. GAPDH was used for normal-
ization. FC (controls n = 15, sCJD MM1; n = 11, sCJD VV2; n = 11), 
CB (controls n = 12, sCJD MM1; n = 12, sCJD VV2; n = 10). c RT-
qPCR analysis of TREM2 in the FC of sCJD (MM1 and VV2), and 
FTD-TDP. For each neurodegenerative dementia, data were compared 
to age and sex-matched controls. CJD (controls n = 14, sCJD (MM1 
and VV2); n = 22), FTD-TDP-43 (controls n = 17, FTD-TDP-43; 
n = 16). d Representative western blot analysis of TREM2 in the FC 
and CB of control, sCJD MM1, and sCJD VV2 cases. TREM2 imma-
ture (TREM2i) and mature (TREM2m) forms are indicated. For nor-
malization β-actin was used. Graphical representation of western blot 
data acquired from the analysis of FC (controls n = 8, sCJD MM1; 
n = 8, sCJD VV2; n = 10) and CB (controls; n = 8, sCJD MM1; n = 8, 
sCJD VV2; n = 8) is shown; *p < 0.05, **p < 0.01, ***p < 0.001. e 
TREM-2 immunohistochemistry in frontal cortex and cerebellum 
in control cases, and then in frontal cortex in CJD MM1. In control 
and CJD cases, TREM2 immunoreactivity is localized in the blood 
vessels (thick arrows); in CJD, TREM2 immunoreactivity is also 
observed in glial cells with the morphology of microglia (long thin 
arrows); scale bar = 30 µm. f TREM2 double-labelling immunofluo-
rescence and confocal microscopy in FC of sCJD showing TREM2 
localization in a subset of microglial cells identified with the anti-
body Iba1 (white arrows). Nuclei are stained with  DRAQ5™ (blue); 
scale bar = 20 µm. g Correlation analysis between TREM2 and CD68 
mRNA in the FC of sCJD cases (n = 28). cc: correlation coefficient
◂
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FC of sCJD cases correlated positively with the macrophage 
marker CD68 (n = 28, cc = 0.4701, p = 0.0116) (Fig. 1g).
In contrast, immunohistochemistry with the anti-TREM2 
Abcam antibody showed neuronal immunoreactivity in con-
trol and diseased cases, in addition to immunostaining of the 
blood vessel walls and rare microglia (data not shown). We 
tried to reproduce these observations using another batch 
but the TREM2 Abcam antibody is a discontinued product 
and no longer available.
Next, we explored whether ADAM10, the main TREM2 
sheddase responsible for its regulated intramembrane pro-
teolysis [60], was also altered in sCJD patients. With RT-
qPCR analysis, no alterations in ADAM10 mRNA levels 
were observed in sCJD, either in the FC (controls, n = 15; 
Fig. 2  ADAM10 expression in 
sCJD brain tissue. a RT-qPCR 
analysis of ADAM10 in the fron-
tal cortex (FC) and cerebellum 
(CB) of control, sCJD MM1, 
and sCJD VV2 cases. GAPDH 
was used for normalization. FC 
(controls n = 15, sCJD MM1; 
n = 11, sCJD VV2 n = 10), CB 
(controls n = 12, sCJD MM1; 
n = 12, sCJD VV2 n = 10). b 
Representative western blot 
analysis of ADAM10 in the FC 
and CB of control, sCJD MM1, 
and sCJD VV2 cases. ADAM10 
precursor (ADAM10p) and 
mature (ADAM10m) forms 
are indicated. β-actin was used 
for normalization. Graphical 
representation of western blot 
data acquired from the analysis 
of FC (controls n = 12, sCJD 
MM1; n = 12, sCJD VV2; 
n = 12) and CB (controls; n = 9, 
sCJD MM1; n = 10, sCJD VV2; 
n = 10); *p < 0.05, **p < 0.01, 
***p < 0.001. c ADAM10 
immunohistochemistry in the 
frontal cortex (FC), cerebellum 
(Cb), and subcortical white mat-
ter (WM) in control and sCJD 
MM1. ADAM10 immunoreac-
tivity is observed in neurons in 
the FC and granule cells (gr) of 
cerebellum, but Purkinje cells 
(P) are very weakly stained or 
not at all. No positive cells are 
distinguished in the white mat-
ter; scale bar = 20 µm
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sCJD MM1, n = 14 and sCJD VV2, n = 10) or in the CB 
(controls, n = 12; sCJD MM1, n = 12 and sCJD VV2, n = 10) 
(Fig. 2a). TREM2 levels were normalized to GAPDH, and 
similar results were obtained for GUSB normalization (data 
not shown). In contrast, ADAM10 precursor and mature 
forms were increased in western blot in the FC of sCJD 
MM1 (p < 0.05 precursor, p < 0.001 mature) and sCJD VV2 
(p < 0.01 precursor, p < 0.001 mature) compared to con-
trols (Fig. 2b). In the CB, ADAM10 levels were not signifi-
cantly different for sCJD compared to controls (p > 0.05 in 
all comparisons) (Fig. 2b). In both brain regions, 10 con-
trols, 8 sCJD MM1, and 8 sCJD VV2 cases were used. The 
ADAM10 antibody showed suboptimal results for immu-
nohistochemistry; ADAM10 immunostaining was weak 
and blurred. ADAM10 immunoreactivity was moderate in 
neurons of the FC, weaker in the granular cells of the cer-
ebellum and negative in Purkinje cells, in control and sCJD 
MM1 cases (Fig. 2c). sCJD VV2 was not analysed. Incuba-
tion with only the secondary antibody showed no immuno-
reactions (data not shown).
Regional and temporal TREM2 expression 
in the brain of sCJD mouse models
To investigate the regional and temporal alterations of 
TREM2 during prion pathogenesis in brain tissue, we 
took advantage of two sCJD mouse models recapitulating 
the molecular and pathological alterations of sCJD MM1 
(tg340-sCJD MM1) and sCJD VV2 (tg360-sCJD VV2) sub-
types [9, 10, 34]. Trem2 mRNA expression was investigated 
in the anterior and posterior cortex, cerebellum, olfactory 
bulb, and brainstem at pre-clinical (80 dpi), early clinical 
(120 dpi), and clinical (180 dpi) disease stages (n = 4–8) 
(Fig. 3). At the clinical stage, Trem2 mRNA was increased 
in all brain regions in both CJD models. Increased Trem2 
expression was also observed at early-clinical stages in the 
anterior cortex of both models. Differences between sCJD 
models were detected in the posterior cortex, where Trem2 
was specifically increased at preclinical and early-clinical 
stages in the tg340 sCJD model and in the cerebellum, where 
Trem2 mRNA expression was specifically increased at early-
clinical stages in the tg361 sCJD model (Fig. 3).
sTREM2 in the CSF of prion diseases
The presence of increased TREM2 expression and ADAM10 
expression and activation in the brain of sCJD raised the 
possibility that sTREM2 could be differentially altered in 
biological fluids of sCJD cases. CSF TREM2 concentra-
tions were assessed in HC, ND, prion diseases from spo-
radic, genetic and acquired aetiology, AD, and MS (Table 1). 
sTREM2 was associated neither with age at onset nor with 
sex (Table 1), both when all cases were analysed together 
and when stratified between non-prion and prion diseases.
Compared to HC and ND, sTREM2 concentrations were 
significantly higher in all types of prion diseases, with the 
exception of FFI cases (Fig. 4a). sTREM2 mean concentra-
tions were higher in ND (2413 ± 1262 pg/mL) than in HC 
(1901 ± 878 pg/mL). Accordingly, the AUC derived from the 
sCJD vs. HC comparison (0.90) was higher than that for the 
sCJD vs. ND comparison (0.85) (Fig. 4b). An optimal cut-
off of 2650 pg/mL sTREM2 discriminated HC from sCJD 
cases with 79% sensitivity and 94% specificity, while a cut-
off of 2850 pg/mL sTREM2 discriminated ND from sCJD 
cases with 77% sensitivity and 80% specificity. AUCs for the 
discrimination of gCJD E200K, gCJD V210I, and iCJD from 
HC and ND showed a good diagnostic accuracy ranging 
from 0.78 to 0.90 (compared to HC) and from 0.73 to 0.85 
(compared to ND). In contrast, sTREM2 showed no diag-
nostic value in distinguishing HC and ND from FFI cases 
(AUC 0.62 and 0.51, respectively) (Fig. 4b). sTREM2 was 
also quantified in AD cases. Mean sTREM2 concentrations 
in AD were slightly higher than in HC and ND; however, 
differences did not reach statistical significance (Table 1 
and Fig. 4a). In contrast, sTREM2 levels were significantly 
higher in sCJD and gCJD-V210I compared to AD (Fig. 4a). 
sTREM2 levels were also assessed in two series of MS cases 
using different populations and different methods. sTREM2 
levels in the CSF were not altered in MS when compared 
with controls (data not shown).
Next, we explored the influence of codon 129 polymor-
phism in PRNP on sTREM2 levels. The highest sTREM2 
concentrations were detected in sCJD cases harbouring 
methionine/methionine (MM; 7884 ± 6652 pg/mL, n = 32), 
followed by methionine/valine (MV; 5257 ± 4061 pg/mL, 
n = 19) and valine/valine (VV; 4183 ± 3803 pg/mL, n = 17). 
Statistical differences were detected between MM and 
VV cases (p = 0.03) (Fig. 5a). pROC analysis revealed a 
superior CSF sTREM2 diagnostic accuracy for sCJD MM 
compared to sCJD VV cases, both when compared to HC 
(AUC = 0.94 vs 0.82, p = 0.0177) and to ND (AUC = 0.90 
vs. 0.74, p = 0.0076) (Fig. 5a).
We further evaluated CSF sTREM2 in the two most 
prevalent sCJD subtypes (MM1 and VV2) in those cases 
with prion type available from autopsy analysis. sCJD MM1 
(8196 ± 7782 pg/mL, n = 20) presented higher sTREM2 
concentrations than sCJD VV2 cases (3224 ± 2200 pg/mL, 
n = 9) (Fig. 5b). In line with these observations, AUC val-
ues were significantly different between the two subtypes 
when compared to HC (AUC = 0.95 vs 0.81, p = 0.0151) and 
ND (AUC = 0.90 vs. 0.73, p = 0.0070) (Fig. 5b), indicating 
a significantly higher diagnostic value of sTREM2 in the 
discrimination of sCJD MM1 cases. Regarding genetic prion 
diseases, gCJD-E200K and FFI cases were stratified accord-
ing to their PRNP codon 129 genotype, which influences 
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their clinicopathological features [17, 47]. sTREM2 con-
centrations were not different between gCJD-E200K-MM 
(n = 33) and gCJD-E200K-MV (n = 22) cases (p = 0.59) 
nor between FFI-MM (n = 16) and FFI-MV (n = 10) cases 
(p = 0.61) (data not shown).
Cerebrospinal fluid tests sTREM2 in sCJD displayed 
a positive correlation with t-tau (n = 126, cc = 0.3424, 
Fig. 3  mRNA Trem2 expression 
in the brain of sCJD MM1 and 
VV2 mouse models. RT-qPCR 
analysis Trem2 expression in 
mouse models of sCJD MM1 
(tg340-CJD MM1) (left panels) 
and sCJD VV2 (tg361-CJD 
VV2) (right panels) subtypes. 
Trem2 expression was analysed 
in five brain regions: anterior 
and posterior cortex, cer-
ebellum, olfactory bulb, and 
brainstem, at three time points: 
pre-clinical (80 days post 
inoculation (dpi)), early-clinical 
(120 dpi), and clinical (180 
dpi). CJD-inoculated animals 
(black columns) were compared 
to their corresponding control-
inoculated animals (white 
columns). Four to eight animals 
per time point and condition 
were used. Normalization was 
performed using the house-
keeping gene Hprt; *p < 0.05, 
**p < 0.01
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p < 0.001) (Fig. 5c), and was associated with 14-3-3 posi-
tivity, since sCJD cases presenting a positive 14-3-3 test 
(n = 118) showed higher sTREM2 concentrations than 
those with a negative (or inconclusive) 14-3-3 test (n = 21) 
(p = 0.03) (Fig. 5d). Additionally, sTREM2 correlated with 
YKL-40 concentrations (n = 47, cc = 0.3240, p = 0.0263) 
(Fig. 5e).
To investigate a potential influence of the disease stage 
at which the LP was performed and sTREM2 concentra-
tions in sCJD patients, samples were stratified in early 
(7914 ± 5924 pg/mL, n = 9), middle (8229 ± 7854 pg/mL, 
n = 20), and late (6794 ± 4950 pg/mL, n = 35) stages, but 
no significant differences were detected between groups 
(Fig. 5f). In 14 individuals, serial LPs at different disease 
stages were available allowing investigation of whether 
sTREM2 values increased during disease progression 
(Fig. 5g). Using a multilevel linear model, we observed a 
significant increase of 1962 pg/mL (95% CI 811–3113) per 
disease stage (p = 0.0036). CSF sTREM2 concentrations 
were not significantly associated with total disease duration 
(cc = − 0.1040, p = 0.2408) (Fig. 5h), ruling out a potential 
role of CSF sTREM2 as sCJD prognostic marker.
sTREM2 in the plasma of sCJD
Soluble TREM2 concentrations in plasma have been 
reported to be in the same range as detected in the CSF 
[52]. Thus, we explored whether sTREM2 in plasma could 
be altered in sCJD compared to HC. Plasma sTREM2 in 
HC and sCJD was associated neither with age at onset nor 
with sex (Table 2). In sCJD, sTREM2 (8981 ± 8932 pg/mL) 
was significantly increased compared to HC (4409 ± 3961) 
(p < 0.001) (Table 2, Fig. 6a), with an AUC value of 0.80 in 
the discrimination of both diagnostic groups (Fig. 6b).
sTREM2 concentrations in sCJD were associated neither 
with PRNP codon 129 genotype: MM (9755 ± 10,492 pg/
mL, n = 59), MV (8238 ± 4220  pg/mL, n = 8) and VV 
(7787 ± 2773 pg/mL, n = 14) (p > 0.05 in all comparisons) 
(Fig. 6c) nor with sCJD subtype: MM1 (10,040 ± 11,570, 
n = 45) and VV2 cases (7106 ± 2147, n = 12) (p = 0.8654) 
(Fig. 6d). In a subset of sCJD cases where plasma-CSF 
paired data were available (n = 31), sTREM2 showed a 
significant correlation between the fluids (cc = 0.3671, 
p = 0.0422) (Fig. 6e). Plasma sTREM2 showed a mod-
est positive correlation with plasma YKL-40 (n = 63, 
cc = 0.2958, p = 0.0217) (Fig. 6f) Nfl (n = 40, cc: 0.4719, 
p = 0.0021) (Fig.  6g) and t-tau (n = 40, cc = 0.3392, 
p = 0.0322) (Fig. 6h) concentrations.
No significant differences in plasma sTREM2 were 
detected between the different disease stages at which blood 
was obtained: early (8258 ± 3842 pg/mL, n = 14), middle 
(7852 ± 5371 pg/mL, n = 15), and late (9768 ± 10,699 pg/
mL, n = 53) stages (p > 0.05 in all comparisons) (Fig. 6i).
Similar to CSF sTREM2, plasma sTREM2 was not 
associated with sCJD disease duration (cc = − 0.1053, 
p = 0.3463) (Fig. 6j).
Discussion
In the present study, we report TREM2 expression and 
levels in the brain and biological fluids of prion diseases, 
with special focus on sCJD, uncovering its potential role 
as a diagnostic marker. In sCJD, we observed a significant 
increase in TREM2 mRNA compared with controls and 
Fig. 4  CSF sTREM2 in the 
diagnosis of prion diseases. a 
CSF sTREM2 concentrations 
in HC (n = 48), ND (n = 64), 
sCJD (n = 139), gCJD-E220K 
(n = 57), gCJD-V210 (n = 34), 
FFI (n = 26), iCJD (n = 10), 
and AD (n = 35). b Area under 
the curve (AUC) derived from 
receiver operating character-
istic (ROC) curves with 95% 
confidence interval (95% CI) for 
CSF sTREM2 in the discrimi-
nation of prion diseases and AD 
from HC and ND; *p < 0.05, 
***p < 0.001
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Fig. 5  CSF sTREM2 in sCJD: association with codon129 genotype, 
sCJD subtype, CSF biomarkers, and clinical data. a CSF sTREM2 
concentrations stratified by prion protein gene (PRNP) codon 129 
polymorphism (M = methionine, V = valine). sCJD MM; n = 32, 
sCJD MV; n = 19 and sCJD VV; n = 17. Mean ( +), median (horizon-
tal bar inside the box) and interquartile ranges are represented. Area 
under the curve (AUC) values with 95% confidence intervals (95% 
CI) indicated for each comparison. b CSF sTREM2 concentrations 
stratified by sCJD subtype MM1 (n = 20) and VV2 (n = 9). Mean 
( +), median (horizontal bar inside the box), and interquartile ranges 
are represented. Area under the curve (AUC) values with 95% confi-
dence intervals (95% CI) indicated for each comparison. c Correlation 
analysis between CSF TREM2 and CSF t-tau (n = 126). d Associa-
tion analysis of CSF TREM2 concentrations with CSF 14-3-3 positiv-
ity. 14-3-3 positive cases; n = 118 and 14-3-3 negative cases; n = 21. 
Mean ( +), median (horizontal bar inside the box), and interquartile 
ranges are represented. e Correlation analysis between CSF sTREM2 
and CSF YKL-40 (n = 47). f CSF sTREM2 concentrations stratified 
by disease stage at the time of lumbar puncture (LP). Samples were 
grouped into three categories according to whether they underwent 
LP in the first (< 0.33), second (0.33–0.66) or third (> 0.66) stage of 
the disease. Early disease stage, n = 15; middle disease stage, n = 21; 
late disease stage, n = 60. Mean ( +), median (horizontal bar inside 
the box), and interquartile ranges are represented. g Longitudinal 
analysis of CSF TREM2 concentrations in cases with available LP 
at different disease stages (n = 14). h Correlation analysis between 
sTREM2 concentrations and disease duration (months) (n = 126). cc: 
correlation coefficient; *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 6  Plasma sTREM2 
in sCJD: association with 
codon129 genotype, sCJD sub-
type, plasma biomarkers, and 
clinical data. a Plasma sTREM2 
concentrations in HC (n = 97) 
and sCJD (n = 86) cases. b Area 
under the curve (AUC) derived 
from receiver operating char-
acteristic (ROC) curves with 
95% confidence interval (95% 
CI) for plasma sTREM2 in the 
discrimination of sCJD from 
HC. c Plasma sTREM2 con-
centrations stratified by prion 
protein gene (PRNP) codon 129 
polymorphism (M = methionine, 
V = valine). sCJD MM; n = 59, 
sCJD MV; n = 8 and sCJD 
VV; n = 14. Mean ( +), median 
(horizontal bar inside the box), 
and interquartile ranges are 
represented. d Plasma sTREM2 
concentrations stratified by 
sCJD subtype MM1 (n = 45) 
and VV2 (n = 12). Mean ( +), 
median (horizontal bar inside 
the box) and interquartile ranges 
are represented. e Correlation 
analysis between plasma and 
CSF sTREM2 (n = 31). Correla-
tion analysis between plasma 
sTREM2 and plasma YKL-40 
f (n = 63), plasma Nfl (n = 40) 
g and plasma t-tau (n = 40) h. i 
Plasma sTREM2 concentrations 
stratified by disease stage at the 
time of blood uptake. Samples 
were grouped into three catego-
ries according to whether they 
underwent blood uptake in the 
first (< 0.33), second (0.33–
0.66), or third (> 0.66) stage of 
the disease. Early disease stage, 
n = 14; middle disease stage, 
n = 15; late disease stage, n = 53. 
Mean ( +), median (horizontal 
bar inside the box), and inter-
quartile ranges are represented. 
j Correlation analysis between 
plasma sTREM2 concentrations 
and disease duration (months) 
(n = 82). cc: correlation coef-
ficient; ***p < 0.001
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FTLD-TDP43. TREM2 protein is increased in the FC and 
CB of sCJD post-mortem-human brain tissue at the protein 
level (both in its immature and mature forms), as revealed 
with western blotting. Immunohistochemistry using the 
anti-TREM2 antibody from RD Systems (AF1828) shows 
TREM2 expression in blood vessels and microglia. Neurons 
are also stained using goat anti-TREM2 Abcam antibody 
in our cases. TREM2 immunoreactivity has been reported 
in neurons, astrocytes, and oligodendrocytes using goat 
anti-TREM2 Abcam antibody in another study [11]. Since 
there is no evidence of neuronal TREM2 mRNA produc-
tion in neurons, and the Abcam antibody is discontinued, 
we assume that additional studies are needed to postulate 
TREM2 as a neuronal marker.
The positive correlation between TREM2 and the mac-
rophage marker CD68 at the mRNA level supports immuno-
histochemical findings and suggests that microglia account 
for the increased TREM2 expression in sCJD brain. This 
observation, in conjunction with increased ADAM10 
expression and activation, points to a potential increase of 
sTREM2 in biological fluids of prion diseased patients.
In agreement with this hypothesis, sTREM2 dis-
plays good accuracy in discriminating sCJD from ND 
(AUC = 0.85) and HC (AUC = 0.90) in CSF, and from HC 
(AUC = 0.80) in plasma. This despite diagnostic accuracies 
being lower than those reported for CSF biomarkers cur-
rently used in clinical settings (14-3-3, t-tau (p-tau/t-tau) and 
RT-QuIC) [13, 36, 44, 62]. The CSF sTREM2 increase in 
gCJD and iCJD is in line with the similar clinicopathologi-
cal features of both conditions with sCJD, and consequently, 
with their fluid biomarkers profiles [32, 38]. In contrast, CSF 
sTREM2 is not altered in FFI, in agreement with the low 
sensitivity of prion disease biomarkers in this condition [40], 
most likely reflecting the restricted pathological alterations 
in terms of neuroinflammation and longer disease duration 
compared with CJD cases [8].
Previous studies have shown slightly or moderately 
increased sTREM2 levels in the CSF in patients with AD 
[22, 24, 55, 67, 68]. Moreover, individuals with MS and 
other inflammatory CNS diseases show increased CSF 
sTREM levels [1, 48, 78]. However, we have not found sig-
nificant differences in the CSF levels of sTREM2 in AD and 
MS cases in our series. We can interpret these discrepancies 
due to lower discrimination capacity of our methods when 
compared with those used in other labs. If this hypothesis is 
true, the present findings reinforce the magnitude of sTREM 
alterations in prion diseases when compared with AD and 
MS.
Interestingly, and in contrast to TREM2, sCJD neuroax-
onal damage markers with exclusive neuronal expression 
such as t-tau and 14-3-3 display reduced protein levels in 
sCJD brain tissue [39]. CSF sTREM2 correlates with the 
neuronal damage markers t-tau and 14-3-3 and with the 
astrocytic marker YKL-40. Similarly, plasma sTREM2 posi-
tively correlates with YKL-40, t-tau, and Nfl. The moder-
ate but significantly positive association between CSF and 
plasma sTREM2 in sCJD cases, similar to what is observed 
in AD [4], suggests that plasma sTREM2 may reflect the 
CNS neuroinflammatory profile in these conditions. How-
ever, the reported expression of TREM2 in non-CNS tis-
sues [14, 74], especially in pathological conditions, does not 
rule out a potential contribution of these tissues to plasma 
sTREM2 concentrations and could explain the differing 
influence of PRNP codon 129 and sCJD subtype between 
CSF and plasma.
The influence of PRNP codon 129 on CSF sTREM2 
(higher concentrations in MM compared to VV cases) is 
different to that reported for neuronal damage markers such 
as CSF t-tau and 14-3-3, which display significantly lower 
values in CJD MV cases compared to homozygotes [19, 27], 
and is explained by the less severe phenotype and longer 
disease duration of CJD MV cases.
Importantly, the increased CSF TREM2 concentrations in 
sCJD MM compared to sCJD VV cases led to significantly 
better AUC values in MM cases, reaching high discrimina-
tory power compared to controls (HC, AUC = 0.94 and ND, 
AUC = 0.90). Thus, data on PRNP polymorphism (routine 
test in prion diagnostic centres) may improve the accuracy 
of CSF sTREM2 in terms of disease diagnosis and should be 
taken into consideration in patient stratification when used as 
a potential surrogate endpoint in disease-modifying therapy.
The reason for increased CSF sTREM2 in sCJD MM1 
compared to sCJD VV2 remains unknown, but it could 
be explained by the higher microglial profile in the corti-
cal regions of sCJD MM1 compared with VV2 cases [34]. 
This, together with the observation that increased TREM2 
expression is more significant in FC than in CB, suggests 
that sTREM2 derived from cortical regions is the main con-
tributor to its increased concentrations in biological fluids.
Another interesting finding in our study is the obser-
vation that sCJD mouse models have increased TREM2 
levels, occurring in some brain regions at pre-clinical and 
early-clinical stages in a regional and disease subtype-spe-
cific manner. This is in line with the observation that CSF 
sTREM2 concentrations are sCJD-subtype-specific and 
independent of the disease stage at which sampling is per-
formed. It is therefore tempting to speculate that sTREM2 
alterations in biological fluids may occur at early disease 
stages. Unfortunately, the absence of a prodromal stage of 
sCJD precludes the study of pre-clinical cases and leaves 
this possibility open for the analysis of sTREM2 in asymp-
tomatic gCJD cases associated with the E200K and V210I 
mutations.
In contrast with longitudinal data from neuroaxonal/syn-
aptic damage markers such as t-tau, 14-3-3, Nfl, and α-syn, 
which present marginal or absent alterations of their CSF 
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concentrations along disease progression [33, 59, 77], the 
progressive neuroinflammatory profile in sCJD brain may 
explain increased CSF sTREM2 concentrations in follow-up 
LPs, suggesting a potential role for sTREM2 as a candidate 
marker of microglial activation. The observation that CSF 
and plasma sTREM2 are not associated with disease dura-
tion in sCJD precludes a prognostic value for sTREM2.
In conclusion, we have found expression of TREM2 in a 
subpopulation of microglial cells in human sCJD brains, with 
increased mRNA and protein levels in brain compared to con-
trols. Further, we have shown that CSF and plasma sTREM2 
have diagnostic accuracy in the discrimination of sCJD. We 
may speculate that sTREM2 quantification in CSF may be 
useful for complementary diagnostic purposes. However, the 
assessment of TREM2 levels in the CSF in other neurological 
diseases, that may represent clinical diagnosis difficulties with 
CJD, is a pending condition. Unfortunately, adequate numbers 
of samples from cases with paraneoplastic encephalitis, other 
rare encephalitis, and rapid forms of non-prionic dementia 
were not available in the present study. Finally, our data high-
light the importance of molecular neuropathology assessment 
in the context of biomarker research toward understanding 
of the aetiology of the alterations detected in biological flu-
ids, which in turn may be relevant in the interpretation of the 
translational value of biomarker profiles.
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